You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
京新藥業(002020.SZ):擬斥資2.05億元收購沙溪製藥100%股權 打造沙溪涼茶、康復新液等中藥大品種
格隆匯 12-15 08:29

格隆匯12月15日丨京新藥業(002020.SZ)公佈,2021年12月14日,公司召開第七屆董事會第二十八次會議,審議通過了《關於收購廣東沙溪製藥有限公司100%股權暨關聯交易的議案》,同意公司以自有資金2.05億元收購元金健康持有的廣東沙溪製藥有限公司(簡稱“沙溪製藥”)99%股權及京新控股持有的沙溪製藥1%的股權。該次交易構成關聯交易。

沙溪製藥主要從事中成藥的研發、生產和銷售,是商務部首批“中華老字號”企業;獨家產品“沙溪涼茶”被列入廣東省和國家非物質文化遺產名錄。經過多年培育,沙溪製藥已發展成擁有先進的生產、檢驗設備,全面符合GMP標準的現代化中藥企業,較好達成公司併購條件

公司已通過元金健康間接持有沙溪製藥39.44%的股權,該次收購沙溪製藥100%股權的交易,可有效整合公司中藥產業資源,綜合利用品牌、文化、渠道優勢,打造沙溪涼茶、康復新液等中藥大品種,實現已有中藥業務的積極發展,符合公司中藥板塊產業發展規劃、有利於進一步提升公司總體經營業績,實現公司的可持續發展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account